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While selective overexpression of serum clinical biomarker Human epididymis secretory
protein 4 (HE4) is indicative of ovarian cancer tumorigenesis, much is still known
about the mechanistic role of the HE4 gene or gene product. Here, we examine the
role of the secretory glycoprotein HE4 in ovarian cancer immune evasion. Through
modified subtractive hybridization analyses of human peripheral blood mononuclear cells
(PBMCs), we have characterized gene targets of HE4 and established a preliminary
mechanism of HE4-mediated immune failure in ovarian tumors. Dual specificity
phosphatase 6 (DUSP6) emerged as the most upregulated gene in PBMCs upon
in vitro exposure to HE4. DUSP6 was found to be upregulated in CD8+ cells and
CD56+ cells. HE4 exposure reduced Erk1/2 phosphorylation specifically in these cell
populations and the effect was erased by co-incubation with a DUSP6 inhibitor,
(E)-2-benzylidene-3-(cyclohexylamino)-2,3-dihydro-1H-inden-1-one (BCI). In co-culture
with PBMCs, HE4-silenced SKOV3 human ovarian cancer cells exhibited enhanced
proliferation upon exposure to external HE4, while this effect was partially attenuated
by adding BCI to the culture. Additionally, the reversal effects of BCI were erased in
the co-culture with CD8+ / CD56+ cell deprived PBMCs. Taken together, these findings
show that HE4 enhances tumorigenesis of ovarian cancer by compromising cytotoxic
CD8+ and CD56+ cells through upregulation of self-produced DUSP6.
Keywords: HE4, ovarian cancer, DUSP6, CD8T cells, tumor immunology
INTRODUCTION
Epithelial ovarian cancer (EOC) is the fifth leading cause of cancer death in women, and the
deadliest of all gynecologic cancers. The American Cancer Society estimates that in 2017, there will
be an estimated 22,440 new cases of EOC and 14,080 deaths in the United States1 Unfortunately,
only 15% of patients are diagnosed at an early stage when the disease is fundamentally curable,
1What Are the Key Statistics About Ovarian Cancer? Available online at: https://www.cancer.org/cancer/ovarian-cancer/
about/key-statistics.html
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keeping the 5-year survival rate at a dismal 46%2. Recurrence
following initial treatment is common, occurring in
approximately 80% of cases, with all recurrent disease patients
eventually succumbing to their illness (Kim et al., 2012). These
dire statistics highlight the need for continued research into
improved diagnostic and treatment options for EOC patients.
Despite continued efforts, there remains a lack of effective
treatments for EOC. Standard first-line therapy consists of
debulking surgery followed by taxane-platinum chemotherapy
(Kim et al., 2012). While targeted therapies such as bevacizumab
and olaparib are approved to treat EOC, these treatments
have not led to an improvement in overall survival (Yap
et al., 2009). One promising new area of investigation lies
in understanding how tumors develop immune tolerance and
evade elimination by cytotoxic lymphocytes. Immune checkpoint
molecules such as PD-1, CTLA4, TIM3, IDO, and others
act to suppress T cell activation, therefore helping tumor
cells escape immune targeting and elimination (Zhao and
Subramanian, 2018). Nivolumab, a monoclonal antibody that
binds to PD-1, preventing it from binding to its tumor cell
associated ligands, PDL1/PDL2, has greatly improved survival
for metastatic melanoma patients (Volpe et al., 2017). Anti-
PD-1 therapies have also been studied in relapsed platinum-
resistant EOC; however, overall response rates do not exceed
15% (Mittica et al., 2016). The inefficacy of immune checkpoint
inhibitors observed in EOC is likely due to compensatory
immune suppressive pathways (Curran et al., 2010; Holmgaard
et al., 2013) or activation of oncogenic pathways that promote
immune tolerance (Zhao and Subramanian, 2018). Overall, a
greater understanding of factors that contribute to immune
evasion in EOC is required in order to develop treatments
that have the ability to reactivate the body’s immune response
to tumors.
Human epididymis protein-4 (HE4) is a member of the whey
acidic four-disulfide core protein family (Bingle et al., 2002). HE4
is elevated in tumor tissue and serum of EOC patients, and is
included in the Risk of Ovarian Malignancy Algorithm (ROMA)
score, along with the biomarker CA125 and menopausal status.
The ROMA score is used in the diagnosis and management
of EOC (Hellström et al., 2003; Moore et al., 2009). ROMA
shows greater sensitivity and specificity for the detection and
monitoring of EOC than the Risk of Malignancy Index, which
uses CA125, pelvic sonography, and menopausal status (Moore
et al., 2009). HE4 also has the advantage of presenting fewer
false positives than CA125 in the case of benign gynecologic
disorders (Hellström et al., 2003; Moore et al., 2012). In vitro
and in vivo studies have shown that HE4 promotes multiple
aspects of ovarian cancer aggression, including tumor growth,
proliferation, metastasis, chemoresistance, and anti-estrogen
resistance (Lu et al., 2012; Zhuang et al., 2013, 2014; Zhu et al.,
2013, 2016; Lokich et al., 2014; Moore et al., 2014; Wang et al.,
2015; Ribeiro et al., 2016; Lee et al., 2017). Clinically, patients with
high levels of serum HE4 are more chemoresistant to traditional
platinum-based therapies and exhibit a poorer prognosis (Angioli
2SEER Cancer Statistics Review, 1975-2014, National Cancer Institute. Available
online at: https://seer.cancer.gov/csr/1975_2014/
et al., 2014; Chudecka-Głaz et al., 2014; Moore et al., 2014; Vallius
et al., 2014). Our group has also hypothesized that HE4 may
play a role in the promotion of immune evasion in EOC. We
determined that HE4 has the ability tomediate gene expression in
peripheral bloodmononuclear cells (PBMCs), and then evaluated
HE4’s effect on one of its identified targets, DUSP6, ultimately
investigating how this relationship affects immune cytotoxicity
against ovarian cancer cells.
MATERIALS AND METHODS
Subtractive Hybridization and TA-cloning
5 × 107 PBMCs from single donor were suspended in 5mL
of serum free RPMI1640 medium (Invitrogen, 31800) and
incubated with or without 0.01µg/mL of rHE4 (Abcam,
ab184603) for 6 h, and total RNA was isolated using TRIzolTM
Reagent (Invitrogen, 15596018). Next, mRNA was purified
using MagnosphereTM UltraPure mRNA Purification Kit
(Takara-Clontech, 9186). From the 5 µg of mRNA, subtractive
cDNA libraries were constructed using PCR-SelectTM cDNA
Subtraction Kit (Takara-Clontech, 637401) following the
manufacturer’s protocols (Figure S1A). PCR products of the
differentially expressed genes were cloned into a pUC19-TA
vector. Top 10 competent cells (Invitrogen, C404003) were
transformed with the clones and were seeded on Xgal/IPTG
containing LB/ampicillin plates. The colonies of clones
containing the inserts were selected by blue/white selection
and were amplified by direct colony PCR using LA Taq R© DNA
polymerase (Takara-Clontech, RR002A) and M13 primers
(Table S1). PCR products in the range of 200 to 3000 bp were
then subjected to direct sequencing (Figures S1B,C).
Cell Culture
Primary human PBMCs were obtained under the auspices of
Women & Infants Hospital IRB approval from total blood of
four individual volunteers by density gradient centrifugation
using Histopaque R©-1077 (Sigma-Aldrich, 10771). The human
ovarian tumor cell line, SKOV3, human NK cell line, NK-
92MI, and human T cell lines, TALL-104 and H9, were obtained
from ATCC (HTB-77, CRL-2408, CRL-11386 and HTB-176,
respectively). RPMI1640 was used for culturing PBMCs and
lymphocyte lines. DMEM (Invitrogen, 31600) was used to culture
SKOV3 cells. Conditioned media was obtained from 24-h PBMC
culture. Residual rHE4 in the conditioned media was deprived
as follows: 5mL of media was incubated with 10 µg (100
µL) of anti-human HE4 antibody (Santa Cruz Biotechnology,
sc-293473) for 1 h at 4◦C. Then, 100mL packed volume of
protein G coated sepharose beads (GE Healthcare Life Science,
17061801) were added to the media and incubated for 4 h at
4◦C. After the incubation, the sepharose beads were removed
by centrifugation and the supernatants were processed through
a sterile 0.2µm pore syringe filter. Concentrations of HE4 in
the conditioned media were confirmed by ELISA (Table S2).
For the cell-mediated cytotoxicity assay, 1 × 106 /well (6-
well plates for caspase-3 western blotting), 5 × 105/well (4-
chamber slide for Ki-67 immunostaining) or 1 × 103/well of
(96-well plates for proliferation assay) target cells (SKOV3)
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were seeded and incubated overnight with complete media. The
next day, cells were placed in serum free media for another
overnight incubation and then effector cells (PBMCs) were
added. The ratio of the effector cells to the target cells was
decided based on a previously published study (Song et al.,
2012). In that study, various ratios of PBMC:SKOV3 (80:1, 40:1,
20:1 or 10:1) were applied for the cell mediated cytotoxicity
assay. In the present study, considering an in vivo environment
where there would be more tumor cells than the infiltrating
mononuclear cells, we chose a lower PBMC ratio (5:1). Some
of the cultures contained 0.01µg/mL of rHE4 and 1µM of
the DUSP6 inhibitor (E)-2-benzylidene-3-(cyclohexylamino)-
2,3-dihydro-1H-inden-1-one (BCI; Sigma-Aldrich, B4313). After
a12-h incubation, the effector cells were washed away and
SKOV3 cells were evaluated for proliferation indicated by either
Ki67 staining or cleaved caspase-3 levels. All experiments were
performed under serum free condition.
Flow Cytometry
FITC-labeled anti CD3, CD4, CD8, CD14, CD19, and CD56
antibodies were obtained from BD Biosciences (555916, 561005,
560960, 555397, 555412, and 562794, respectively). Alexa Fluor R©
647-conjugated anti DUSP6 antibody was obtained from Abcam
(ab200751). Alexa Fluor R©647-conjugated anti phosphor-p44/42
MAPK antibody was obtained from Cell Signaling Technology
(13148). After staining for cell surface markers (CD3, CD14,
CD19 and CD56) the cell membrane was permeabilized by
0.2% Triton X-100 and 0.2% digitonin, and then stained
for DUSP6 or phosphor-p44/42-MAPK. FITC-labeled mouse
IgG1κ (BD55748) and Alexa Fluor R© 647-labeled mouse IgG1κ
(BD55783) were used as isotype controls. Flow cytometric
analysis was performed with FACSCanto system and FACSDiva
software (BD Biosciences).
Quantitative Real-Time PCR
RNA was isolated from cells using TRIzol (Invitrogen, A33250)
according to the manufacturer’s instructions. cDNA was
synthesized using SuperScript III reverse transcriptase
(Invitrogen, 18080093). qPCR was performed using Premix
Ex-TaqTM II (Clontech-Takara, 639676) probes for DUSP6. All
reactions were normalized using GAPDH as an endogenous
control. Amplification data were analyzed using the 11Ct
method. Sequences of PCR primers are summarized in Table S1.
ELISA
ELISA kits for HE4 and DUSP6 were obtained from My
BioSource (MBS280223 and MBS073193, respectively). Assays
were performed following the manufacturer’s instruction.
Western Blotting
Phosphorylation of Erk1/2 in NK-92MI, TALL-104 and H9 cell
lines were assessed by western blotting. Apoptosis in SKOV3 cells
was evaluated as the ratio of cleaved caspase-3 to intact caspase-
3 on the western blotting gel. Antibodies against phosphorylated
total Erk1/2 MAPK and cleaved caspase-3 were obtained from
Cell Signaling Technology (9101 4695 and 9661). An antibody
against intact caspase-3 was obtained from Abcam (ab13847).
The results were visualized with SuperSignalTM West Pico
chemiluminescent substrate (Thermo Fisher Scientifics, 34080)
and analyzed with the UN-SCAN-IT gel software for Windows
(Silk Scientific Inc.).
HE4 Silencing With shRNA
shRNA for human HE4 (Origene, TR318721) were transfected
into SKOV3 using Lipofectamine R© 2000 (Invitrogen, 11668)
following the manufacture’s instruction. Individual single cells
were selected by culturing under the pressure of 5µg/mL
of puromycin (Research Products International, 58-58-2).
Phenotypes of the clones were evaluated by western blotting
using anti-HE4 antibody (Origene, TA801137; Figure S2).
Cell Proliferation Assay
1 × 103/well of SKOV3 cells were seeded in each well of a
96-well culture plate. After overnight incubation with serum
free medium, 5 × 103/well of effector cells (PBMCs) were
added to the quiescent cells. After 12-h incubation, the effector
cells were washed away and cells were incubated under serum
free conditions for 24, 48, and 72 h. Cell proliferations were
evaluated using fluorescent-based CEllTiter-Blue R© (Promega,
G8080) and Spectra Max Gemini EM fluorescent micro plate
reader (Molecular Devices).
Immunohistochemistry
5 × 105/chamber of SKOV3 cells were seeded in a 4-chamber
slide. After overnight incubation with serum free medium, 2.5
× 106/chamber of effector cells (PBMCs) were added to the
quiescent cells and the cells were cultured for 48 h. Ki67 positive
cells were counted in 20 of 200x fields. Affinity purified normal
mouse IgG1 (Santa Cruz Biotechnology, sc-3877) was used as
a negative control. A mouse anti-Ki67 monoclonal antibody
was purchased from BD Biosciences (550609). An alkaline
phosphatase (ALP) labeled anti-mouse IgG secondary antibody
and an ALP substrate kit were obtained from Vector laboratories
(AP-2000, SK-5100).
Depletion of CD8+ and CD56+ Cells
From PBMCs
CD8+ and CD56+ cells were removed from PBMCs using
magnetic CD8 and CD56 MicroBeads (Miltenyi Biotec, 130-045-
201 and 130-050-401) with autoMACS cell separator (Miltenyi
Biotec, 130-092-545). Briefly, 5× 107 of PBMCs were suspended
in 60 µL of separation buffer (PBS, pH 7.2 with 0.5% BSA
and 2mM EDTA), and then 20 µL each of CD8 and CD56
MicroBeads were added, followed by a 15min incubation at
4◦C. After washing, cells were resuspended in 500 µL of
the separation buffer and magnetic separation was performed
using autoMACS R© Columns (Miltenyi Biotec, 130-021-101).
Unlabeled cells that passed through were collected and combined
with total effluent from the washed column. Efficacy of the
depletion was evaluated by two-color flow cytometry using FITC-
labeled anti-CD8 antibody (BD Biosciences, 560960) and PE-
labeled anti-CD56 antibody (BD Biosciences, 561903, Figure S3).
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Statistics
Data was expressed as an average ± SEM of at least four
independent experiments. An unpaired, two-tailed Student t-test
was used to determine significance. Multiple treatments were
analyzed by using one-way ANOVA followed by Ryan’s multiple
comparison test. Differences between groups were considered
statistically significant when p < 0.05.
RESULTS
Differential Expression of PBMC Genes
After HE4 Exposure
To identify differentially expressed genes after HE4 exposure,
modified subtractive hybridization was performed as depicted in
Figure S1A. PCR products of the differentially expressed genes
were cloned into pUC19-TA vectors to create a differential cDNA
library (Figures S1B,C). PCR products from 250 HE4-induced
and HE4-suppressed gene colonies were sequenced, resulting
in the identification of 209 induced genes and 206 suppressed
genes. Among the identified genes, 20 induced and 13 suppressed
sequences showed no significant similarity (NSS) to known genes
in available nucleotide databases. Among the 209 induced genes,
dual specificity phosphatase 6 (DUSP6) emerged as one of the
most frequently identified genes (3 times out of 250 sequences,
1.2%; Table 1).
HE4 Induces DUSP6 Expression in PBMCs
HE4-induced upregulation of DUSP6 in PBMCs was then
confirmed via three modalities: quantitative PCR (qPCR), ELISA
and flow cytometry. First, PBMCs were harvested after a 6 h
exposure with recombinant human HE4 (rHE4; 0.01µg/mL),
revealing a 1.60± 0.13-fold increase (p< 0.01) in DUSP6 mRNA
production (Figure 1A). The concentrations of DUSP6 in PBMC
lysates (9.38 ± 0.62 vs. 15.62 ± 0.97 ng/mL, p < 0.01) and
culture supernatants (0.77 ± 0.10 vs. 1.43 ± 0.14 ng/mL, p <
0.01) after a 24 h exposure to rHE4 were also increased (Table 2).
PBMCs were then cultured with rHE4 for 24 h and collected for
flow cytometry analysis. Protein expression of DUSP6 in CD3+
PBMCs (T cells) was found to be significantly increased with HE4
exposure (34.4 ± 0.6% vs. 47.0 ± 3.2% of total CD3+ cells; p
< 0.05; Figures 1B,C left panel). DUSP6 expression in CD56+
cells (NK/T cells, NK cells) was also increased to a lesser extent
(34.1 ± 2.3 vs. 41.7 ± 1.7% of total CD56+ cells; p < 0.05;
Figures 1B,C right panel). Insignificant changes were observed
in DUSP6 expression amongst CD14+ (monocytes) and CD19+
(B cells), as shown in Figure S4. In order to identify a T cell
subset involved in the HE4 responsive induction of DUSP6,
two-color flow cytometry using anti-DUSP6 antibody and anti-
CD4 (helper T cell) or CD8 (cytotoxic T cell) antibodies were
performed. As shown in Figures 2A,B, after a 24 h exposure to
rHE4, CD8+ T cells (9.9± 0.8% vs. 1.9± 0.1%; p < 0.01) but not
CD4+ T cells (15.6 ± 1.4% vs. 15.4 ± 1.5%) exhibited significant
DUSP6 induction. These finding suggested that the CD8+ and
CD56+ cytotoxicmononuclear cells were responsible for theHE4
responsive DUSP6 induction.
TABLE 1 | Genes induced in response to HE4.
Frequency ID Gene name
20 NSS No significant similarity
3 NG_033915 Dual specificity phosphatase 6 (DUSP6)
3 XM_017002424 Capping actin protein of muscle Z line alpha sub
unit 1 (CAPZA1)
3 NM_001402 Eukaryotic translation elongation factor 1 alpha 1
(EEF1A1)
3 XM_017000674 FGR proto-oncogene, SRC family tyrosine kinase
(FGR)
3 NM_001261446.1Thioredoxin reductase 1 (TXNRD1)
3 NM_021109 Thymosin beta 4, X-linked (TMSB4X)
3 BC006364 Tubulin folding cofactor D
2 AK223032 Beta actin variant
2 AC008397.7 Chromosome 19 clone CTC-251H24
2 NM_001170330 Chromosome 4 open reading frame 3 (C4orf3)
2 AY430097 DAZ associated protein 2 (DAZAP2)
2 NM_001005360 Dynamin 2 (DNM2)
2 NG_002350.4 Eukaryotic translation elongation factor 1 alpha 1
pseudogene 5 (EEF1A1P5)
2 NM_004468.4 Four and a half LIM domains 3 (FHL3)
2 NM_001077488 GNAS complex locus (GNAS)
2 NM_001321232 Histocompatibility (minor) HA-1 (HMHA1)
2 NM_000206.2 Interleukin 2 receptor, gamma (IL2RG)
2 NM_001127605.2Lipase A, lysosomal acid (LIPA)
2 NM_012335.3 Myosin IF (MYO1F)
2 XM_011541520 Notch 2 (NOTCH2)
2 NM_001165412 Nuclear factor of kappa light polypeptide gene
enhancer in B-cells 1 (NFKB1)
2 NM_020820.3 Phosphatidylinositol-3,4,5-trisphosphate
dependent Rac exchange factor 1 (PREX1)
2 NM_001251855 Phosphoinositide-3-kinase regulatory subunit 5
(PIK3R5)
2 NM_201384.2 Plectin (PLEC)
2 NM_002952 Ribosomal protein S2 (RPS2)
2 NM_001007.4 Ribosomal protein S4, X-linked (RPS4X)
2 NM_000655 Selectin L (SELL)
2 NM_004252 SLC9A3 regulator 1 (SLC9A3R1)
2 NM_022733.2 Small ArfGAP2 (SMAP2)
2 NM_001278206 Solute carrier family 43, member 3 (SLC43A3)
2 NM_025250.2 Tweety family member 3 (TTYH3)
2 BC050652.1 Zinc finger, DHHC-type containing 16
2 NM_004773 Zinc finger, HIT-type containing 3 (ZNHIT3)
2 XM_011516569 Zyxin (ZYX)
1 155 genes
CD8+ and CD56+ Cytotoxic Lymphocytes
Are Targets of HE4 Induced DUSP6
In order to identify effector cells for HE4 induction of DUSP6,
two-color flow cytometry using antibodies against phosphor-
Erk1/2 (pErk1/2) and CD4, CD8, CD14, CD19, and CD56
were performed. Significant decreases of pErk1/2+ populations
were observed in CD8+ (30.2 ± 2.4% vs. 4.3 ± 0.2% in total
CD8+ cells; p < 0.01) and CD56+ (32.3 ± 4.0% vs. 5.4 ±
0.6% in total CD56+ cells; p < 0.01) cells after a 24 h rHE4
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FIGURE 1 | HE4 upregulates expression of DUSP6 in PBMCs. (A) DUSP6
transcription in response to a 6-hr incubation with 0.01 mg/mL rHE4 (HE4) or
equivalent amount of PBS (CTR) were evaluated by triplicated trials of real time
PCR using PBMCs from four individual donors. (B) Two-color flow cytometric
analysis of PBMC following 24-h incubation with 0.01 mg/mL of rHE4 (HE4) or
vehicle (CTR). 2D-scatterplots of DUSP6 (Alexa Fluor 647) and CD3 or CD56
(FITC) are shown. Numbers on the plots indicate mean percentages of the cell
populations of the each tetrameric area from four independent experiments.
(C) Bar graphs from flow cytometric analyses using PBMCs from four
individual donors. The mean ± SEM are shown. *p < 0.05, **p < 0.01.
(0.01µg/mL) exposure. These decreases were abrogated by co-
treatment with 1µM of the DUSP6 inhibitor (E)-2-benzylidene-
3-(cyclohexylamino)-2,3-dihydro-1H-inden-1-one (BCI) in both
CD8+ cells and CD56+ cells (23.3 ± 0.7% and 30.5 ± 2.6%,
respectively; Figures 3A,B). Insignificant changes were observed
in pErk1/2+ populations in CD4+, CD14+, and CD19+ cells as
shown in Figure S5.
TABLE 2 | DUSP6 concenrations in cell lysates and culture media of PBMC.
Cell Lysates* Culture Media**
CTR HE4 CTR HE4
9.38 ± 0.62 15.62 ± 0.97*** 0.77 ± 0.10 1.43 ± 0.14***
ng/mL
* In 2.5 mg/ml of total protein.
** In 5mL media of 5 × 106 PBMC culture.
The mean ± SEM are shown. ***p < 0.01 vs. CTR.
Next, CD56+ NK cell line (NK92MI), CD8+ cytotoxic T
cell line (TALL-104) and CD4+ helper T cell line (H9) were
incubated with the conditioned media from a 24 h PBMC culture
with or without rHE4 and BCI for 1 h. Residual rHE4 in
the conditioned media was deprived by immunoprecipitation
(Table S2). The lysates of the cells were used for western blotting
to evaluate Erk1/2 phosphorylation. As shown in Figures 3C,D,
1 h incubation with the HE4 exposed PBMC conditioned media
suppressed Erk1/2 phosphorylation in NK92MI cells (0.67 ±
0.07-fold vs. CTR, p < 0.01) and TALL-104 cells (0.56 ± 0.10-
fold vs. CTR, p < 0.01) but not in H9 cells (1.01 ± 0.03-
fold vs. CTR). The rHE4 responsive pErk1/2 suppressions were
abrogated by the PBMC conditioned media from co-treatment
with rHE4 and BCI in both NK92MI (0.90 ± 0.04-fold vs.
CTR) and TALL-104 (0.89 ± 0.06-fold vs. CTR). Finally, the
cell lines were seeded at 1 × 106/mL density. Twelve hours
later, the cells were deprived of serum overnight. The quiescent
cells were incubated for 24 h with or without 0.01µg/mL of
rHE4, and then the concentrations of DUSP6 were determined
in the cell lysates containing 2.5 mg/mL of proteins or culture
supernatants (SN). As shown in Figure 3E, NK92MI and TALL-
104 showed significant increases in DUSP6 concentrations in
response to rHE4 exposure both in lysates and culture SN (KI,
92MI; lysate, 8.76 ± 0.27 vs. 13.33 ± 0.28 ng/mL, SN, 1.88 ±
0.08 vs. 2.83 ± 0.10, TALL-104; lysate, 11.00 ± 0.32 vs. 13.82
± 0.33, SN, 2.85 ± 0.09 vs. 3.64 ± 0.19, p < 0.01). On the
other hand, H9 showed no significant response to rHE4 (lysate,
4.44 ± 0.17 vs. 4.85 ± 0.38, SN, 1.04 ± 0.07 vs. 1.13 ± 0.05).
These findings suggested that HE4 induced DUSP6 acts as an
autocrine suppressor for Erk1/2 MAPK in CD8+ and CD56+
cytotoxic lymphocytes.
HE4 Attenuates Ovarian Cancer
Susceptibility to PBMC
Mediated Cytotoxicity
In order to evaluate the impact of HE4 on PBMC cytotoxicity
against cancer cells, the human ovarian tumor cell line, SKOV3,
was co-cultured with PBMCs (5× 106/mL density). To minimize
the effect of native HE4 produced by tumor cells, the SKOV3
cells were stably transfected with HE4 specific shRNA (shHE4).
A clone of shRNA transfected cells used in this experiment was
tested for its phenotype by western blotting (Figure S2). After
incubation at 37◦C for various lengths of time, concentrations
of HE4 in the media were measured by ELISA (Table S3). HE4
concentrations in the media of the HE4 suppressed SKOV3
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FIGURE 2 | HE4 upregulates expression of DUSP6 in peripheral CD8+ T
cells. Two-color flow cytometric analysis of PBMCs following 24-h incubation
with 0.01 mg/mL of rHE4 (HE4) or vehicle (CTR). (A) 2D-scatterplots of
DUSP6 (Alexa Fluor 647) and CD4 or CD8 (FITC) are shown. Numbers on the
plots indicate mean percentages of the cell populations of the each tetrameric
area from four independent experiments. (B) A bar graph from flow cytometric
analyses using PBMCs from four individual donors. The mean using ± SEM
are shown. *p < 0.01.
cells were below detection limit at any point up to 72 h (data
not shown).
After 12 h incubation, the effector cells (PBMCs) were washed
away, and the target cells (SKOV3) were analyzed by three
independent modalities: cell proliferation, Ki67 immunostaining,
and western blotting for intact and cleaved caspase-3. First,
SKOV3 cells co-cultured with PBMC suspensions containing
0.01µg/mL of rHE4 showed significantly more proliferation than
cells cultured with the rHE4 free suspensions at 24 (1222.70 ±
29.48 vs. 1517.98 ± 34.32, p < 0.01), 48 (2038.38 ± 55.94 vs.
3508.64 ± 164.98, p < 0.01) and 72 h (1983.33 ± 100.41 vs.
2935.89 ± 116.47, p < 0. 01), and the accelerated proliferations
were partially abrogated by adding 1µM of BCI to the culture
(1295.68 ± 39.87, 2667.27 ± 95.13, and 2424.50 ± 105.70, at 24,
48, and 72 h, respectively Figure 4A).
Second, immunohistochemistry using anti-Ki67 was
performed to evaluate the proliferation activities of SKOV3
cells in the presence of PBMCs with or without rHE4 and BCI
for 24 h. Affinity purified normal mouse IgG1 (Santa Cruz
Biotechnology, sc-3877), which was the identical isotype to the
anti-Ki67 antibody, was used for isotype control. The number of
Ki67 positive tumor cells in rHE4-containing PBMC suspension
was higher than the cells in rHE4-free suspension, and the
increased activity was partially attenuated by adding BCI to the
culture (27.6± 1.7%, 68.5± 2.6%, and 48.9± 2.3%, respectively;
Figures 4B,C). Incubation with BCI (1µM) alone showed no
significant effects on the proliferation of SKOV3 cells.
Finally, protein lysates from the target cells were subjected
to western blotting for caspase-3. As shown in Figures 4D,E,
SKOV3/PBMC co-cultures with rHE4 led to a significant
decrease in ratios of cleaved caspase-3 to intact caspase-3 (10.0
± 1.4% vs. 1.0 ± 0.7%, p < 0.01), and the tolerance of
target cells was partially reversed by adding BCI to the culture
(4.9 ± 0.9%, p < 0.01 vs. CTR and HE4). Incubations with
BCI (1µM) alone showed no significant effects on SKOV3
cell proliferation, Ki67 expression, or apoptosis. These findings
suggest that HE4 enhances tolerance of cancer cells against
immunocompetent mononuclear cells via the up-regulation
of DUSP6 in PBMCs. In order to confirm involvement of
CD8+/CD56+ cytotoxic lymphocytes in the HE4 induced
immunomodulation, the co-culture study was repeated using
PBMCs deprived of CD8+/CD56+ cells (Figure S3). As shown
in Figures 5A–E, all the effects of BCI shown in Figure 4 were
erased in the CD8+/CD56+ cell free co-cultures, suggesting that
cytotoxic lymphocytes play a pivotal role in immunoediting by
DUSP6 up-regulation in response to HE4 exposure.
DISCUSSION
Several studies from our laboratory and elsewhere have
revealed multidimensional roles for HE4 in the pathogenesis
of ovarian cancer, including the promotion of tumor growth,
chemoresistance, anti-estrogen resistance, invasion, migration,
and adhesion (Lu et al., 2012; Zhuang et al., 2013, 2014; Zhu
et al., 2013, 2016; Lokich et al., 2014; Moore et al., 2014; Wang
et al., 2015; Ribeiro et al., 2016; Lee et al., 2017). In this present
study, we have begun to delineate another vital function of HE4
in disrupting immune cell function, which has implications for
immune system targeting of tumor cells. DUSP6, which we found
to be upregulated by rHE4 treatment in CD8+ T cells and CD56+
NK cell subsets of PBMCs, is likely one key mediator of this effect
in these immune cell subsets.
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FIGURE 3 | HE4 suppresses Erk1/2 phosphorylation in CD8+ and CD56+ cells via DUSP6 induction. Two-color flow cytometric analysis of PBMC following 24-hr
incubation with PBS (CTR), rHE4 (0.01mg /mL) and BCI (1mM) as indicated. (A) 2-D scatterplots of phosphor-Erk1/2 (Alexa Fluor 647) and CD8 or CD56 (FITC) are
shown. (B) Mean ± SEM from analyses of phosphor-Erk1/2 positive cells from four individual donors are shown in the bar graph. (C) Immunoblotting for
phosphor-Erk1/2 in CD56+ NK92MI, CD8+ TALL-104 and CD4+ H9 cells following 1-h incubation with the conditioned media from 24-h PBMC culture with rHE4
(0.01 mg/mL) and BCI (1mM) in the indicated combinations. Blots of total Erk1/2 are shown as loading controls. (D) Bar graph represents the relative band densities
to controls. Mean ± SEM are shown (n = 4). (E) DUSP6 concentrations in cell lysates and culture supernatants (SN) after 24 h incubation with or without rHE4 (0.01
mg/mL). Mean ± SEM are shown (n = 4). *p < 0.05, **p < 0.01, n.s., not significant.
DUSP6 is a member of the DUSP family that
dephosphorylates threonine and tyrosine residues on MAPK
substrates. It specifically dephosphorylates ERK, a member of
the MAPK family that also includes p38 and JNK. MAPKs
are activated by growth factors, cytokines, integrin ligands, and
stress signals to regulate growth, survival, apoptosis, and immune
response in diverse cell types. Interestingly, DUSP6 is expressed
at low levels in resting cells and is actually stimulated by ERK
activation, promoting a negative feedback loop on ERK activity
(Bermudez et al., 2010). This early response of DUSP6 to ERK
activation could explain the apparently contradictory activation
of ERK by HE4 in cancer cells (Lu et al., 2012; Zhu et al., 2013;
Ribeiro et al., 2016; Lee et al., 2017) and our current results
here showing HE4 upregulation of DUSP6 expression leading to
suppression of ERK phosphorylation in PBMC subsets.
Several reports reveal a role for DUSP6 in development,
organogenesis, and cancer (Bermudez et al., 2010). However, its
effect on cancer progression is highly dependent upon the type of
cancer and even the stage. For example, in pancreatic cancer, it
is upregulated in early stages but is often completely diminished
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FIGURE 4 | Responses of SKOV3 cells to co-culture with PBMCs were evaluated. Cells were co-cultured with PBMCs (5 × 106/mL) alone (CTR) or PBMCs with rHE4
(0.01mg /mL) and BCI (1mM) in indicated combinations. (A) Cell proliferation was assessed at 24, 48, and 72 h of the culture (n = 10). (B) Ki67 immunohistochemistry
staining was performed on SKOV3 cells co-cultured with PBMCs for 24 h. Ki67+ cells are identified with red nuclear staining. Cells incubated with normal mouse IgG1
were shown as an isotype control. (C) Bar graph represents the percentage of Ki67+ cells in total countable cells under 200x fields (n = 20). (D) A representative
image of western blotting for intact and cleaved caspase-3 of SKOV3 lysates following 6-h PBMCs co-culture with of rHE4 (0.01 mg/mL) and BCI (1mM) as indicated.
(E) Bar graph represents the percentage of cleaved caspase-3 relative to intact caspase-3 (n = 4). Mean ± SEM are shown in the bar graphs. *p < 0.01.
as the tumor progresses toward the invasive ductal carcinoma
state (Furukawa et al., 2005). In lung cancer, it has been shown
to act as a tumor suppressor (Okudela et al., 2009); conversely, it
is upregulated in glioblastoma and HER2-positive breast cancer
(Lucci et al., 2010; Messina et al., 2011). One report found that
its downregulation in ovarian cancer results in hyperactivation
of ERK and subsequent chemoresistance (Chan et al., 2008).
These discrepancies are likely due to variable deregulation of ERK
signaling and compensatory pathways that are highly context
dependent (Bermudez et al., 2010).
While much is still not understood regarding the role
of tumor-produced DUSP6 on tumorigenesis, the function
of DUSP6 originating from immune cells is even less well
studied. Other members of the DUSP family, including DUSP1,
DUSP2, and DUSP10, are known to have roles in immune
response (Bermudez et al., 2010), and a few reports suggest
that DUSP6 does as well. Elevated DUSP6 was shown to
cause downregulation of ERK phosphorylation in CD4+ T
cells in elderly individuals, who have suppressed immune
responses (Li et al., 2012). Another report confirmed this
age associated rise in CD4+ T cell DUSP6 expression, and
found that young immunosuppressed patients with end stage
renal disease have DUSP6 levels comparable to elderly healthy
individuals (Huang et al., 2017). One study found that DUSP6
downregulates ERK activity in CD4+ T cells and increases
their regulatory T cell functions (Bertin et al., 2015). Together,
these reports suggest that higher levels of DUSP6 contribute
to immune suppression. It has also been shown that DUSP6
is downregulated in T cells upon IL-2 withdrawal (Chechlinska
et al., 2009), and IL-2 was found to upregulate DUSP6 gene
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FIGURE 5 | Responses of SKOV3 cells to co-culture with CD8+/CD56+ cell free PBMCs (5 × 106 / mL) were evaluated. Cells were co-cultured with CD8+/CD56+
cell-free PBMCs alone or CD8−/CD56− PBMCs with rHE4 (0.01 mg/mL) and BCI (1mM) in indicated combinations. (A) Cell proliferation was assessed at 24, 48, and
72 h of the culture (n = 10). (B) Ki67 immunohistochemistry staining was performed on SKOV3 cells co-cultured with CD8+/CD56+ cell-free PBMCs for 24 hrs.
Ki67+ cells are identified with red nuclear staining. Cells incubated with normal mouse IgG1 were shown as an isotype control. (C) Bar graph represents the
percentage of Ki67+ cells in total countable cells under 200x fields (n = 20). (D) A representative image of western blotting for intact and cleaved caspase-3 of
SKOV3 lysates following 6-h CD8+/CD56+ cell free PBMCs co-culture with of rHE4 (0.01 mg/mL) and BCI (1mM) as indicated. (E) Bar graph represents the
percentage of cleaved caspase-3 relative to intact caspase-3 (n = 4). Mean ± SEM are shown in the bar graphs. *p < 0.01, n.s., not significant.
expression in T cells (Kovanen et al., 2005). Since IL-2
stimulates cytotoxic T cell expansion and activation as well
as that of immune suppressive regulatory T cells (Boyman
and Sprent, 2012), it remains to be determined how the
IL-2 responsiveness of DUSP6 plays into its apparent effect
on immune suppression, and how this relates to tumor
immune response.
Although much remains unknown regarding the specific
effects of DUSP6 on cancer progression and tumor immunity,
our findings begin to reveal some novel insights. We report
for the first time that HE4-mediated upregulation of DUSP6
in CD8+ T cell and CD56+ NK cell subsets of PBMC cells
leads to the inhibition of their cytotoxic activity against SKOV3
ovarian cancer cells. While DUSP6 has been connected to
immune function of CD4+ T cells, our results reveal that the
subsets of lymphocytes affected byDUSP6 are context dependent.
Further investigation into the inhibitory effects of DUSP6 in these
different populations will be illuminating. Moreover, we have
begun to establish HE4 as a critical regulator of immune cell
function, which deepens our understanding of the mechanistic
role HE4 plays in ovarian cancer pathogenesis.
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